Skip to content

Study of Biomarker From Blood and Tissue of Head and Neck Carcinoma

Study of Previously Collected Blood and Tissue Samples From Patients With Nasopharyngeal Carcinoma,Laryngeal Carcinoma and Hypopharyngeal Carcinoma

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01171235
Enrollment
200
Registered
2010-07-28
Start date
2010-07-31
Completion date
2012-12-31
Last updated
2010-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laryngeal Neoplasms, Pharyngeal Neoplasms

Keywords

Laryngeal Neoplasms, Pharyngeal Neoplasms

Brief summary

The aim of the study is to find for one or more serum or tissue markers of molecular biology in head and neck cancer patients used for early diagnosis, predicting prognosis and being sensitive to chemotherapy and radiotherapy

Detailed description

Head and neck malignant tumors, especially nasopharyngeal carcinoma in southern China with the high incidence, its incidence, treatment, prognosis or tumor markers in serum has been a hot research with little progress.In our study, we collect NPC-based collection including the blood samples of laryngeal, hypopharyngeal cancer, separating serum and white blood cells stored in -80 degrees,while tissues are frozen in liquid nitrogen and embedded in paraffin。 Patient treatment and prognosis are combined in order to find for markers of molecular biology used for early diagnosis, predicting prognosis and being sensitive to chemotherapy and radiotherapy.

Interventions

None listed

Sponsors

Southern Medical University, China
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
15 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* all of nasopharyngeal carcinoma * hypopharyngeal carcinoma or laryngeal carcinoma visited at ENT department of NanFang hospital

Exclusion criteria

* all of above patients whose anticipated survival duration were less than 6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026